Clinical trial · Observational
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the ACTHEON Study is to evaluate the in vitro activity of ceftolozane-tazobactam, imipenem-relebactam and comparator agents (amoxicillin- clavulanate, piperacillin-tazobactam, ceftazidime, cefotaxime, cefepime, imipenem, meropenem, levofloxacin and amikacin; see list more details on page 7) against clinical isolates of P. aeruginosa and Enterobacterales prospectively collected from hematology and oncology patients with complicated intra-abdominal infections (cIAIs), complicated urinary infections (cUTIs), lower respiratory tract infections (LRTIs), and blood stream infections (BSIs) from 15 participating centers in Spain
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ceftolozane/Tazobactam | — | UNRESOLVED | — |
| Hematology and Oncology | — | UNRESOLVED | — |
| Imipenem/Relebactam | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ceftolozane/tazobactam | Drug | — | UNRESOLVED |
| imipenem- relebactam | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- P. aeruginosa isolates
- description
- All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
- interventionNames
- Drug: Ceftolozane/tazobactam
- Drug: imipenem- relebactam
- label
- Enterobacterales isolates
- description
- All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed
- interventionNames
- Drug: Ceftolozane/tazobactam
- Drug: imipenem- relebactam
Primary outcomes (2)
- measure
- Summary MIC and its distributions as susceptible, intermediate and resistant
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * P. aeruginosa isolates * Enterobacterales isolates Exclusion Criteria: * Non P. aeruginosa isolates * Non Enterobacterales isolates
References
Publications (0)
Data not yet available